We are live on ! Find out more
ALZN icon

Alzamend Neuro
ALZN

11 hedge funds and large institutions have $1.67M invested in Alzamend Neuro in 2026 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,270% more capital inflows, than outflows

Capital inflows: $849K | Capital outflows: $62K

18.61% more ownership

Funds ownership: 17.93% → 36.54% (+19%)

15% less funds holding

Funds holding: 13 → 11 (-2)

50% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 4

67% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 3

Holders
11
Holders Change
-2
Holders Change %
-15.38%
% of All Funds
0.13%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
2
Reduced
4
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Kingsbury Capital Investment Advisors
Kingsbury Capital Investment Advisors
Illinois
+$845K
2
Vanguard Capital Management
Vanguard Capital Management
Pennsylvania
+$3.5K
3
IFG Advisory
IFG Advisory
Georgia
+$24

Top Sellers

Rank Fund Capital Flow
1
Geode Capital Management
Geode Capital Management
Massachusetts
-$21.4K
2
Morgan Stanley
Morgan Stanley
New York
-$19.1K
3
Clearstead Advisors
Clearstead Advisors
Ohio
-$10.6K
4
Citigroup
Citigroup
New York
-$5.54K
5
Tower Research Capital (TRC)
Tower Research Capital (TRC)
New York
-$2.96K

ALZN Hedge Fund Activity: Q2 2026 in Review

11 of the 8,379 institutional investors tracked by Wall St. Rank reported a position in Alzamend Neuro (ALZN) for Q2 2026, worth a combined $1.67M — up 131% from $723K a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of ALZN and 1 opened new positions — a net loss of 2 holders — while 4 trimmed existing stakes and 2 added.

The largest buyer was Kingsbury Capital Investment Advisors, adding an estimated $845K. The largest seller was Geode Capital Management, cutting an estimated $21.4K.

  • 11 institutional investors held Alzamend Neuro (ALZN) as of Q2 2026, down from 13 in Q1 2026.
  • Funds reported $1.67M of Alzamend Neuro stock for Q2 2026, up 131% quarter-over-quarter.
  • 1 fund opened new Alzamend Neuro positions in Q2 2026 and 3 closed out, a net change of -2 holders.
  • The largest Alzamend Neuro buyer in Q2 2026 was Kingsbury Capital Investment Advisors, an estimated $845K added.
  • The largest Alzamend Neuro seller in Q2 2026 was Geode Capital Management, an estimated $21.4K sold.

Based on aggregated 13F filings for Q2 2026.